News
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
15 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Reported Late Monday, Everest Medicines And Kezar Life Sciences Received IND Approval From China's NMPA For The PALIZADE Trial In Lupus Nephritis
27 Feb 24
News
Press releases
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8 Apr 24
Press Releases
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
14 Mar 24
Press Releases
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8 Mar 24
Press Releases
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
28 Feb 24
Press Releases
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
26 Feb 24
Press Releases